AGC Biologics

Executive Summary

AGC Biologics is a global contract development and manufacturing organization (CDMO) headquartered in Copenhagen, Denmark, with a focus on biologics, cell and gene therapies. Founded in 2017, the company offers end-to-end development and manufacturing services for protein expression, plasmid DNA (pDNA), mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells. By serving a diverse client base from preclinical to commercial stages, AGC Biologics has positioned itself as a key player in the rapidly growing advanced therapies CDMO market. The company's integrated platform and strategic facility expansions aim to address the increasing demand for outsourced manufacturing of complex biologics and gene therapies. With the global CDMO market projected to expand significantly, AGC Biologics is well-poised for growth driven by its expertise in viral vectors and cell therapies. The company's recent investments in capacity expansion and technology platforms are expected to enhance its competitive edge. However, as a private entity, financial performance is not publicly disclosed, and the company faces competition from larger CDMOs. Overall, AGC Biologics represents a solid investment opportunity within the outsourced manufacturing space, supported by industry tailwinds and its specialized service offerings.

Upcoming Catalysts (preview)

• Q3 2026Completion of new viral vector manufacturing facility (expansion in Copenhagen or US)85% success
• Q4 2026Announcement of multi-year master service agreement (MSA) with a top-20 biopharma for gene therapy production60% success
• Q2 2026FDA or EMA approval of a client's cell/gene therapy product manufactured by AGC Biologics40% success